The purpose of this study is to evaluate whether microneedling RF subcutaneous fat pad thickness in the temple, submental, and cheek regions, to determine whether the addition of topical PLLA after microneedling RF alters or preserves subcutaneous fat pad thickness and to assess patient satisfaction and perceived outcomes following microneedling RF ± PLLA treatment.

Inclusion Criteria:

• Seeking facial rejuvenation for cosmetic concerns
• Able and willing to provide informed consent
• Willing to comply with study procedures and follow-up visits

Exclusion Criteria:

• Prior filler injection or energy-based device treatment to the face within the past 6 months
• Previous facial surgeries
• Pregnant or breastfeeding
• Active infection, dermatitis, or open lesions in the treatment area
• History of keloids or abnormal scarring
• Known allergy to poly-L-lactic acid (PLLA)- Current participation in another clinical trial involving facial aesthetic treatments
• Presence of pre-cancerous or cancerous lesions in the treatment area
• Current or planned use of glucagon-like peptide-1 receptor agonists (e.g., Ozempic, semaglutide) during the study period. Subjects on these medications will be excluded due to potential effects on facial fat and overall weight.
• HIV+ patients
• Patients on HIV medications- Patients that have eczema and rosacea